Revelation Biosciences, Inc. REVB
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 35.46% | 22.52% | 13.12% | 0.09% | -4.49% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 39.01% | 23.27% | 13.74% | -3.44% | -14.92% |
| Operating Income | -39.01% | -23.27% | -13.74% | 3.44% | 14.92% |
| Income Before Tax | -27.03% | 31.49% | 40.73% | 47.61% | 46.78% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -27.03% | 31.49% | 40.73% | 47.61% | 46.78% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -27.03% | 31.49% | 40.73% | 47.61% | 46.78% |
| EBIT | -39.01% | -23.27% | -13.74% | 3.44% | 14.92% |
| EBITDA | -39.16% | -23.37% | -13.80% | 3.47% | 14.99% |
| EPS Basic | 76.96% | -55.75% | -- | -- | -- |
| Normalized Basic EPS | 83.11% | 30.34% | -- | -- | -- |
| EPS Diluted | 76.96% | -55.75% | -- | -- | -- |
| Normalized Diluted EPS | 83.11% | 30.34% | -- | -- | -- |
| Average Basic Shares Outstanding | 3,169.23% | 6,788.79% | -- | -- | -- |
| Average Diluted Shares Outstanding | 3,169.23% | 6,788.79% | -- | -- | -- |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |